Novartis firstly launch a new bone Paget's disease therapy.

Published: 2007-01-31 06:56:00

Updated: 2007-01-31 06:56:00

Novartis Korea has launched the sale of Aclastar (zoledronic acid 5mg injection) for a new treatment of Paget's disease, a class of the biphosphonates, which suppresses re-uptake of destroyed bone cells by administering it via vein slowly for 15 minutes a dose unlike the conventional oral therapy...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK